Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.
Karim Fizazi(Université de Lille), Robert Dreicer(University of Virginia), Albertas Ulys(Vilnius University), George Fountzilas(Hellenic Cooperative Oncology Group), Ronald de Wit(Erasmus MC Cancer Institute), Robert J. Jones(Beatson West of Scotland Cancer Centre), Daniel P. Petrylak(Yale University), Flavio Mavignier Cárcano(Hospital de Câncer de Barretos), Fred Saad(Centre Hospitalier de l’Université de Montréal), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Joaquim Bellmunt(Dana-Farber Cancer Institute), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Niels Borgstein(Ironwood Pharmaceuticals (United States)), Felipe Melo Cruz(Instituto Brasileiro de Controle do Câncer), Neeraj Agarwal(University of Utah), Bindu Tejura(Takeda (United States)), Connie Lee(University of Michigan), David B. Agus(California State University Los Angeles)
Cited by 3
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k